TO THE EDITOR
=============

Postpartum-acquired hemophilia A is a rare and potentially severe complication of pregnancy caused by an autoantibody against factor VIII \[[@ref1]\]. Acquired factor VIII deficiency is associated with autoimmune conditions, neoplastic diseases, drug hypersensitivity, and pregnancy. A retrospective study analyzed 51 published cases of postpartum factor VIII inhibitors, with regard to the outcome according to treatment \[[@ref2]\]. The annual incidence of acquired hemophilia is 0.2-1/1,000,000 and it is difficult to diagnose. Most patients present with major hemorrhage and the mortality rate is about 22% \[[@ref3],[@ref4],[@ref5]\].

A 20-year-old female in the postpartum period presented to the hospital with vaginal hemorrhage that had begun 20 d earlier. Examination of the patient showed that there were no obstetrical or gynecologic pathologies, or acute or chronic diseases causing the hemorrhage. The patient's laboratory data are summarized in the [Table 1](#t1){ref-type="table"}. The patient's activated partial thromboplastin time (APTT) was 68.4 s. A mixing study using a 50:50 mixture of the patient's plasma and control plasma showed no correction suggesting the presence of an inhibitor. The patient's factor VIII inhibitor level was 2.5 BU mL^--1^ (normal: \<0.6 BU mL^--1^). Fresh frozen plasma (174 units), factor VIII (1 unit of VIII:C kg--1 for every 2 percentage point increase in plasma VIII:C), and recombinant FVIIa (Novo-Seven 90 μg kg--1 IV bolus injection, and then the same dose every 3 h for 1 d) was administered; active bleeding was controlled after 2 d of the treatment.

Intravenous immunoglobulin (IVIG, 400 mg kg--1 for 5 d) and IV methylprednisolone (60 mg d--1 for 1 week) was given (as recommended) to eliminate the inhibitor \[[@ref6]\]. At follow-up 7 d after the initiation of treatment the patient was clinically stable with a normal aPTT. Methylprednisolone was initiated at 50 mg d^--1^ 8 d after the start of the initial treatment, and was then gradually tapered and stopped over the course of 6 weeks. The patient was discharged from the hospital 15 days after treatment was initiated.

Factor VIII inhibitor was 0.55 BU 4 weeks after delivery. The patient's postpartum hemorrhage was attributed to the presence of acquired factor VIII inhibitor. Factor VIII inhibitor can be seen in healthy pregnant women without a history of bleeding. Prolonged aPTT and normal PTT is the hallmark of laboratory diagnosis. The objectives of therapy are control of bleeding and elimination of the inhibitor \[[@ref5],[@ref7]\]. Treatment strategies to control active bleeding include the use of factor VIII concentrates, activated prothrombin complex concentrates (anti-inhibitor coagulant complex, Feiba, Autoplex T), and recombinant human factor VIIa \[[@ref6],[@ref8],[@ref9]\]. Elimination of factor VIII inhibitor requires the use of immunosuppressive modalities. A prospective randomized trial evaluated the efficacy of prednisone and cyclophosphamide alone, and the combination of both drugs in 31 non-hemophilic patients with factor VIII antibodies. All patients initially received prednisone (1 mg·kg^--1^·d^--1^ p.o.) for 3 weeks and the antibody disappeared in 10 of the 31 participants (32%) during the initial course of prednisone \[[@ref10]\]. Another option for the treatment of acquired factor VIII inhibitors is administration of IVIG \[[@ref11]\]. Written informed consent was obtained from the patient for publication.

Acquired hemophilia A is a rare and often fatal disorder. Because of difficulties and misdiagnosis delays in diagnosis and treatment are common. As such, whenever acquired hemophilia A---with or without bleeding is suspected immediate consultation with a hemophilia experienced in the management of inhibitors should be initiated.
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###### The patient's laboratory findings.
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